-
1 Comment
Sanofi India Limited is currently in a long term downtrend where the price is trading 1.0% below its 200 day moving average.
From a valuation standpoint, the stock is 33.7% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 6.4.
Sanofi India Limited's total revenue sank by 12.8% to $7B since the same quarter in the previous year.
Its net income has increased by 26.4% to $1B since the same quarter in the previous year.
Finally, its free cash flow grew by 69.3% to $6B since the same quarter in the previous year.
Based on the above factors, Sanofi India Limited gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - General |
| ISIN | INE058A01010 |
| Exchange | NSE |
| CurrencyCode | INR |
| Market Cap | 145B |
|---|---|
| PE Ratio | 38.61 |
| Target Price | 6814 |
| Dividend Yield | 1.9% |
| Beta | 0.07 |
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SANOFI.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
